Ovarian cancer creates a suppressive microenvironment to escape immune elimination

Gynecologic Oncology

Volumn 117, Issue 2, 2010, Pages 366-372

  Yigit, Refika ^a   Massuger, Leon F A G ^a   Figdor, Carl G ^b   Torensma, Ruurd ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ascites; Immune response; Immune suppression; Ovarian cancer; Tregs

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; MACROPHAGE DERIVED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; AUTOIMMUNITY; CANCER STAGING; CANCER SURVIVAL; CELL THERAPY; DENDRITIC CELL; DOWN REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MACROPHAGE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

FEMALE; HUMANS; IMMUNOTHERAPY; OVARIAN NEOPLASMS;

EID: 77950189167     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.01.019     Document Type: Review

References (89)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18 (2007) 581-592
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
3. Dougan M., and Dranoff G. Immune therapy for cancer. Annu. Rev. Immunol. 27 (2009) 83-117
4. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S., et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154 (1995) 3961-3968
5. Tacken P.J., de Vries P.J., Torensma R., and Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7 (2007) 790-802
6. Berchuck A., Iversen E.S., Luo J., Clarke J.P., Horne H., Levine D.A., et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin. Cancer Res. 15 (2009) 2448-2455
7. Maw M.K., Fujimoto J., and Tamaya T. Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers. BMC Cancer 9 (2009) 430
8. Rosenberg S.A., Spiess P., and Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233 (1986) 1318-1321
9. Dudley M.E., and Rosenberg S.A. Adoptive cell transfer therapy. Semin. Oncol. 34 (2007) 524-531
10. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271 (1994) 907-913
11. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
12. Tacken P.J., Torensma R., and Figdor C.G. Targeting antigens to dendritic cells in vivo. Immunobiology 211 (2006) 599-608
13. Wick M., Dubey P., Koeppen H., Siegel C.T., Fields P.E., Chen L., et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186 (1997) 229-238
14. Gajewski T.F., Meng Y., and Harlin H. Immune suppression in the tumor microenvironment. J. Immunother. 29 (2006) 233-240
15. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2 (1996) 1096-1103
16. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., et al. Tumor evasion of the immune system by converting CD4+. J. Immunol. 178 (2007) 2883-2892
17. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., and Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24 (2006) 99-146
18. Saunier E.F., and Akhurst R.J. TGF beta inhibition for cancer therapy. Curr. Cancer Drug Targets 6 (2006) 565-578
19. Moore K.W., de Waal M.R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001) 683-765
20. Salazar-Onfray F. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med. Oncol. 16 (1999) 86-94
21. Elgert K.D., Alleva D.G., and Mullins D.W. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 64 (1998) 275-290
22. Curiel T.J. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117 (2007) 1167-1174
23. Ochsenbein A.F. Immunological ignorance of solid tumors. Springer Semin. Immunopathol. 27 (2005) 19-35
24. Singh S., Ross S.R., Acena M., Rowley D.A., and Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175 (1992) 139-146
25. Quesnel B. Tumor dormancy and immunoescape. APMIS 116 (2008) 685-694
26. Hicklin D.J., Marincola F.M., Ferrone S.H.L.A., and class I. antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 5 (1999) 178-186
27. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J.J., Lopez-Botet M., Duggan-Keen M., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18 (1997) 89-95
28. Liu Z., Guo B., and Lopez R.D. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. J. Gastroenterol. Hepatol. 24 (2009) 900-911
29. Piali L., Hammel P., Uherek C., Bachmann F., Gisler R.H., Dunon D., et al. CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J. Cell. Biol. 130 (1995) 451-460
30. Igney F.H., and Krammer P.H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 71 (2002) 907-920
31. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 1178-1183
32. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89 (2000) 2637-2645
33. Rask K., Zhu Y., Wang W., Hedin L., and Sundfeldt K. Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol. Cancer 5 (2006) 62
34. Jabbour H.N., Milne S.A., Williams A.R., Anderson R.A., and Boddy S.C. Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br. J. Cancer 85 (2001) 1023-1031
35. Li W., Xu R.J., Zhang H.H., and Jiang L.H. Overexpression of cyclooxygenase-2 correlates with tumor angiogenesis in endometrial carcinoma. Int. J. Gynecol. Cancer 16 (2006) 1673-1678
36. Huang M., Stolina M., Sharma S., Mao J.T., Zhu L., Miller P.W., et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58 (1998) 1208-1216
37. Rodriguez P.C., and Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222 (2008) 180-191
38. Frey A.B. Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest. 116 (2006) 2587-2590
39. Scarlett U.K., Cubillos-Ruiz J.R., Nesbeth Y.C., Martinez D.G., Engle X., Gewirtz A.T., et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 69 (2009) 7329-7337
40. Serafini P., Borrello I., and Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16 (2006) 53-65
41. Kooi S., Freedman R.S., Rodriguez-Villanueva J., and Platsoucas C.D. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res. 12 (1993) 429-437
42. Hayashi K., Yonamine K., Masuko-Hongo K., Iida T., Yamamoto K., Nishioka K., et al. Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans. Gynecol. Oncol. 74 (1999) 86-92
43. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003) 203-213
44. Raspollini M.R., Castiglione F., Rossi D.D., Amunni G., Villanucci A., Garbini F., et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann. Oncol. 16 (2005) 590-596
45. Tomsova M., Melichar B., Sedlakova I., and Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol. Oncol. 108 (2008) 415-420
46. Kandalaft L.E., Singh N., Liao J.B., Facciabene A., Berek J.S., Powell Jr. D.J., et al. The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol. Oncol. 116 (2010) 222-233
47. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18538-18543
48. Clarke B., Tinker A.V., Lee C.H., Subramanian S., van de R.M., Turbin D., et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 22 (2009) 393-402
49. Toda A., and Piccirillo C.A. Development and function of naturally occurring CD4+CD25+ regulatory T cells. J. Leukoc. Biol. 80 (2006) 458-470
50. Bluestone J.A., and Abbas A.K. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3 (2003) 253-257
51. Zhou G., and Levitsky H.I. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 178 (2007) 2155-2162
52. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, et al., Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 1-12-2003;102:4107-14.
53. Wei S., Kryczek I., Zou L., Daniel B., Cheng P., Mottram P., et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 65 (2005) 5020-5026
54. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004) 942-949
55. Wolf D., Wolf A.M., Rumpold H., Fiegl H., Zeimet A.G., Muller-Holzner E., et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11 (2005) 8326-8331
56. Napoletano C, Bellati F, Landi R, Pauselli S, Marchetti C, Visconti V, et al. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med in press. "Postprint"; doi:10.1111/j.1582-4934.2009.00911.x.
57. Giuntoli R.L., Webb T.J., Zoso A., Rogers O., az-Montes T.P., Bristow R.E., et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 29 (2009) 2875-2884
58. Leffers N., Gooden M.J., de Jong R.A., Hoogeboom B.N., ten Hoor K.A., Hollema H., et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. 58 (2009) 449-459
59. Freeman G.J., Gribben J.G., Boussiotis V.A., Ng J.W., Restivo Jr. V.A., Lombard L.A., et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262 (1993) 909-911
60. Boussiotis V.A., Freeman G.J., Gribben J.G., Daley J., Gray G., and Nadler L.M. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 11059-11063
61. Young J.W., Koulova L., Soergel S.A., Clark E.A., Steinman R.M., and Dupont B. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J. Clin. Invest. 90 (1992) 229-237
62. Caux C., Vanbervliet B., Massacrier C., Azuma M., Okumura K., Lanier L.L., et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. 180 (1994) 1841-1847
63. Thomas W.D., Smith M.J., Si Z., and Hersey P. Expression of the co-stimulatory molecule CD40 on melanoma cells. Int. J. Cancer 68 (1996) 795-801
64. Vanky F., Hising C., Sjowall K., Larsson B., and Klein E. Interferon-gamma and tumor necrosis factor-alpha treatment of ex vivo human carcinoma cells potentiates their interaction with allogeneic lymphocytes. J. Interferon. Cytokine Res. 16 (1996) 201-207
65. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., and Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174 (1991) 561-569
66. Melichar B., Nash M.A., Lenzi R., Platsoucas C.D., and Freedman R.S. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin. Exp. Immunol. 119 (2000) 19-27
67. Gordon K.J., and Blobe G.C. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta 1782 (2008) 197-228
68. Kriegel M.A., Li M.O., Sanjabi S., Wan Y.Y., and Flavell R.A. Transforming growth factor-beta: recent advances on its role in immune tolerance. Curr. Rheumatol. Rep. 8 (2006) 138-144
69. Young T.N., Rodriguez G.C., Rinehart A.R., Bast Jr. R.C., Pizzo S.V., and Stack M.S. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol. Oncol. 62 (1996) 89-99
70. Rosano L., Varmi M., Salani D., Di Castro V., Spinella F., Natali P.G., et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 61 (2001) 8340-8346
71. Rodriguez G.C., Haisley C., Hurteau J., Moser T.L., Whitaker R., Bast Jr. R.C., et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol. Oncol. 80 (2001) 245-253
72. Maehara Y., Kakeji Y., Kabashima A., Emi Y., Watanabe A., Akazawa K., et al. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J. Clin. Oncol. 17 (1999) 607-614
73. Young T.N., Rodriguez G.C., Moser T.L., Bast Jr. R.C., Pizzo S.V., and Stack M.S. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am. J. Obstet. Gynecol. 170 (1994) 1285-1296
74. Moser T.L., Young T.N., Rodriguez G.C., Pizzo S.V., Bast Jr. R.C., and Stack M.S. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int. J. Cancer 56 (1994) 552-559
75. Fishman D.A., Kearns A., Chilukuri K., Bafetti L.M., O'Toole E.A., Georgacopoulos J., et al. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion Metastasis 18 (1998) 15-26
76. Ellerbroek S.M., Fishman D.A., Kearns A.S., Bafetti L.M., and Stack M.S. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res. 59 (1999) 1635-1641
77. Fishman D.A., Bafetti L.M., Banionis S., Kearns A.S., Chilukuri K., and Stack M.S. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 80 (1997) 1457-1463
78. Norgaard P., Hougaard S., Poulsen H.S., and Spang-Thomsen M. Transforming growth factor beta and cancer. Cancer Treat. Rev. 21 (1995) 367-403
79. Pepper M.S. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 8 (1997) 21-43
80. Curiel T.J., Cheng P., Mottram P., Alvarez X., Moons L., Evdemon-Hogan M., et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64 (2004) 5535-5538
81. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203 (2006) 871-881
82. Kryczek I., Wei S., Zhu G., Myers L., Mottram P., Cheng P., et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67 (2007) 8900-8905
83. Norian L.A., Rodriguez P.C., O'Mara L.A., Zabaleta J., Ochoa A.C., Cella M., et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 69 (2009) 3086-3094
84. Balint K., Conejo-Garcia J.R., Buckanovich R., and Coukos G. Role of vascular leukocytes in ovarian cancer neovascularization. Adv. Exp. Med. Biol. 622 (2008) 273-280
85. Coukos G., Conejo-Garcia J.R., Buckanovich R., and Benencia F. Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. Adv. Exp. Med. Biol. 590 (2007) 185-193
86. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4 (2003) 1206-1212
87. Munn D.H., and Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117 (2007) 1147-1154
88. Okamoto A., Nikaido T., Ochiai K., Takakura S., Saito M., Aoki Y., et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 11 (2005) 6030-6039
89. Leveque L., Deknuydt F., Bioley G., Old L.J., Matsuzaki J., Odunsi K., et al. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. J. Immunother. 32 (2009) 101-108